Compare NextEra Energy, Inc. (NEE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs TG Therapeutics Inc — how do they compare? NextEra Energy, Inc. trades at $88.09 (market cap $183.53B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: NextEra Energy, Inc. is far larger — about 22.2× TG Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 2.83% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NEE | TGTX | |
|---|---|---|
Market Cap | $183.53B | $8.26B |
Sector | Utilities | Health |
52-Week High | $97.88 | $59.06 |
52-Week Low | $69.77 | $26.39 |
Enterprise Value | $285.94B | $8.50B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $87.93, down 0.98% with a bearish technical signal. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though Q4 2025 earnings missed expectations. Recent news highlights the proposed Dominion Energy combination and $59 billion capital expenditure plan through 2032. Analyst consensus remains strongly bullish with 66.7% buy ratings and $101.88 price target, representing 16% upside potential.
NEE offers solid long-term growth prospects from renewable energy expansion and regulatory advantages, but faces execution risks from massive capital spending and integration challenges from the Dominion merger. Current valuation at 22.34 P/E appears reasonable given growth trajectory, though technical weakness suggests near-term consolidation may continue before potential breakout.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
